🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

U.S. FDA authorizes Novavax COVID vaccine for adults

Published 07/13/2022, 04:30 PM
Updated 07/14/2022, 06:26 AM
© Reuters. FILE PHOTO: A Novavax logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
PFE
-
JNJ
-
NVAX
-
MRNA
-

(Reuters) -The U.S. Food and Drug Administration authorized the use of Novavax (NASDAQ:NVAX) Inc's COVID-19 vaccine on Wednesday, clearing the way for a shot whose more traditional technology has raised hopes of wider acceptance among vaccine skeptics.

Shares of Novavax rose 1.3% to $70.89 after its two-dose vaccine became the fourth COVID shot to be authorized for use in adults in the United States.

The U.S. Centers for Disease Control and Prevention (CDC) still needs to sign off on the use of the vaccine before it can be made available to people.

A panel of CDC advisers on vaccines is expected to meet on Tuesday, but the agenda has not been released yet.

Earlier this week, the U.S. government said it had secured 3.2 million Novavax vaccine doses, which it plans to release once the company finishes quality testing in the next few weeks. More than two-thirds of the U.S. population has been fully vaccinated with shots from Moderna (NASDAQ:MRNA) Inc, Pfizer-BioNTech or Johnson & Johnson (NYSE:JNJ). U.S. health officials hope that people who have opted not to take Pfizer (NYSE:PFE) and Moderna's vaccine, which are based on the groundbreaking messenger RNA (mRNA) technology, will instead opt for Novavax's protein-based shot.

The vaccine, already approved in Europe, is based on a technology that has been used for decades to combat diseases including hepatitis B and influenza.

"Today's authorization offers adults in the United States who have not yet received a COVID-19 vaccine another option that meets the FDA's rigorous standards," FDA Commissioner Robert Califf said in a statement.

In Europe, however, demand for the shot has not been significantly high, with about 242,000 doses of the vaccine administered since its launch in December, prompting Novavax to increase its focus on lower-income countries.

© Reuters. FILE PHOTO: A Novavax logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

The company's initial application for U.S. authorization of the shot was delayed by almost a year on development and production problems, making it a late entrant in the country's market for COVID vaccines.

Novavax has projected between $4 billion and $5 billion in sales this year. Analysts expect sales at the lower end of that range, according to Refinitiv.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.